Back HIV Populations Children & Adolescents

Children & Adolescents

AIDS 2016: HIV Treatment Programs Need to Prepare for a "Youth Bulge"

Treatment programs in sub-Saharan Africa must prepare for a growing population of adolescents over the next few years as children born with HIV grow up and begin a transition from child health services to adult clinics, Mhairi Maskew from the University of Witwatersrand told participants at the 21st International AIDS Conference (AIDS 2016) this week in Durban.

alt

Read more:

New HIV Infections Decline by 60% Among Children in Most Affected African Countries

HIV incidence has fallen dramatically for children in the African countries with the highest burdens of the disease, more pregnant women are receiving prophylactic antiretrovirals to prevent transmission, and half of infected children are now on antiretroviral treatment, according to a new UNAIDS report release this month to coincide with the United Nations General Assembly High-Level Meeting on Ending AIDS.

alt

Read more:

April 10 is National Youth HIV and AIDS Awareness Day

April 10 is National Youth HIV and AIDS Awareness Day (NYHAAD), an opportunity to promote education and raise awareness about the epidemic among young people in the U.S. According to the Centers for Disease Control and Prevention (CDC), youth age 13 to 24 accounted for just over a quarter of all new HIV infections in 2010 -- rising to nearly 40% if those up to age 29 are included -- with an especially high burden among young gay and bisexual black and Latino men.

alt

Read more:

FDA Approves Dolutegravir for Smaller Children with HIV

The U.S. Food and Drug Administration this week approved a supplemental indication for the HIV integrase inhibitor dolutegravir (Tivicay), allowing its use for children age 6 years and older who weigh as little as 30 kg. The drug is currently being evaluated in younger and smaller children.

alt

Read more:

CROI 2016: Cotrimoxazole Prophylaxis Provides No Benefit for HIV-Exposed Uninfected Children

Challenging current guidelines, prolonged use of cotrimoxazole may not be necessary for HIV-exposed but uninfected children in low-mortality, non-malarial settings with low risk for late mother-to-child transmission throug breastfeeding, Roger Shapiro told participants at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2016) in Boston.

alt

Read more: